Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Wu CC. Progress of liver resection for hepatocellular carcinoma in Taiwan. Jpn J ClinOncol. 2017;47(5):375–80.
2. Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel. Liver Int. 2014;34(2):174–83.
3. Toro A, Pulvirenti E, Palermo F, Di Carlo I. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. SurgOncol. 2012;21(1):e23–30.
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
5. Yasunaga H, Horiguchi H, Matsuda S, et al. Relationship between hospital volume and operative mortality for liver resection: data from the Japanese Diagnosis Procedure Combination database. Hepatol Res. 2012;42(11):1073–80.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献